Radionuclide Data

Strontium 89

Administered as a sterile, non-pyrogenic, aqueus solution of Strontium-89 Chloride for intravenous administration. The solution contains no preservative.

Each milliliter contains:

Strontium Chloride 10.9 - 22.6 mg
Water for Injection q.s. to 1 mL

The radioactive concentration is 37 MBq/mL (1 mCi/mL), and the specific activity is 2.96-6.17 MBq/mg, 80-167 µCi/mg at calibration. The pH of the solution is 4 - 7.5.


Strontium-89 decays by beta emission with a physical half-life of 50.5 days. The maximum beta energy is 1.463 MeV (100%). The maximum range of β- from Strontium-89 in tissue is approximately 8 mm.

Soluble strontium compounds behave as calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

Strontium-89 Chloride is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose is retained in the bones.

Excretion pathways are two-thirds urinary and one-third fecal in patients with bone metastases. Urinary excretion is higher in people without bone lesions.

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License